RCUS Arcus Biosciences Inc
Price (delayed)
$15.72
Market cap
$1.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.09
Enterprise value
$1.28B
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
Highlights
RCUS's revenue has soared by 104% YoY and by 4.2% QoQ
The gross profit has soared by 104% YoY and by 4.2% from the previous quarter
The net income is up by 13% year-on-year but it is down by 8% since the previous quarter
RCUS's equity is up by 12% year-on-year but it is down by 10% since the previous quarter
RCUS's quick ratio is down by 7% year-on-year
Key stats
What are the main financial stats of RCUS
Market
Valuations
Earnings
Shares outstanding
91.43M
Market cap
$1.44B
Enterprise value
$1.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.25
Price to sales (P/S)
5.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.19
Revenue
$247M
EBIT
-$246M
EBITDA
-$229M
Free cash flow
-$267M
Per share
Balance sheet
Liquidity
EPS
-$3.09
Free cash flow per share
-$2.93
Book value per share
$6.98
Revenue per share
$2.71
TBVPS
$13.02
Total assets
$1.19B
Total liabilities
$551M
Debt
$0
Equity
$635M
Working capital
$823M
Debt to equity
0
Current ratio
5.14
Quick ratio
5.01
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-92.7%
Gross margin
100%
Net margin
-100.8%
Operating margin
-118.6%
Return on assets
-20.9%
Return on equity
-42.9%
Return on invested capital
-29.6%
Return on capital employed
-24.9%
Return on sales
-99.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCUS stock price
How has the Arcus Biosciences stock price performed over time
Intraday
-2.66%
1 week
-8.18%
1 month
8.56%
1 year
-30.13%
YTD
-17.7%
QTD
3.22%
Financial performance
How have Arcus Biosciences's revenue and profit performed over time
Revenue
$247M
Gross profit
$247M
Operating income
-$293M
Net income
-$249M
Gross margin
100%
Net margin
-100.8%
RCUS's revenue has soared by 104% YoY and by 4.2% QoQ
The gross profit has soared by 104% YoY and by 4.2% from the previous quarter
Arcus Biosciences's net margin has soared by 58% YoY but it has decreased by 3.4% from the previous quarter
The operating margin has surged by 54% year-on-year but it has declined by 4.1% since the previous quarter
Growth
What is Arcus Biosciences's growth rate over time
Valuation
What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
2.25
P/S
5.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.19
RCUS's EPS is up by 22% year-on-year
RCUS's price to book (P/B) is 22% lower than its 5-year quarterly average of 2.9 and 13% lower than its last 4 quarters average of 2.6
RCUS's equity is up by 12% year-on-year but it is down by 10% since the previous quarter
RCUS's revenue has soared by 104% YoY and by 4.2% QoQ
RCUS's P/S is 74% below its 5-year quarterly average of 22.1 and 35% below its last 4 quarters average of 8.9
Efficiency
How efficient is Arcus Biosciences business performance
RCUS's return on sales has surged by 58% year-on-year but it is down by 4% since the previous quarter
RCUS's ROIC is down by 8% from the previous quarter but it is up by 3.3% YoY
Arcus Biosciences's return on assets has decreased by 8% QoQ but it has increased by 5% YoY
The return on equity has increased by 6% year-on-year but it has declined by 4.6% since the previous quarter
Dividends
What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCUS.
Financial health
How did Arcus Biosciences financials performed over time
The total assets is 115% greater than the total liabilities
The total liabilities has declined by 16% year-on-year and by 6% since the previous quarter
The total assets has declined by 8% since the previous quarter and by 2.8% year-on-year
Arcus Biosciences's debt is 100% less than its equity
RCUS's equity is up by 12% year-on-year but it is down by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.